



**LUIS CARLOS ORTEGA, MD**

**ADULT & GERIATRIC PSYCHIATRY**

620 S Tonopah Dr. Las Vegas, NV 89106 | T: 702-413-1391 | F: 702-413-1392

**June 07, 2021**

Pharmacy and therapeutic committee

State of Nevada department of health and human services

Division of health care financing and policy

1100 E. William street suite 101, Carson city, Nevada 89701

**RE: Agenda item 6D- discussion and possible adoption of psychotropic agents-antipsychotics-atypical antipsychotics-oral**

To whom it may concern,

On June 24, 2021 silver state scripts board meeting will review caplyta (lumateperone) as first line treatment for patients with schizophrenia. This letter is to request that caplyta be moved from non preferred status on the PDL to a preferred status. Since the launch of caplet in 2020, I have had several patients that have been treated therapeutically and have had favorable results.

I have found that caplets is both efficacious and tolerable for my schizophrenic patients. It is imperative as a psychiatrist to have open access to a branded products as the need of each patient differs. I strongly urge the committee to add caplyta to the PDL as preferred. Thank you for your consideration.

Sincerely,

**Luis Carlos Ortega, MD**

**NV License Number: 6969**

**Date Issued: 12/04/1993**